TIGIT and neoplasm: The drug exposure profiles (as well as binding affinities; Supplementary Figure 1B) of anti-TIGIT: mIgG2a and anti-TIGIT:mIgG1* were found to be comparable (Supplementary Figure 3), suggesting that the differences of anti-tumor efficacy by anti-TIGIT antibodies with different isotypes can be attributed to differences in their biological activities.